◆ NeutralENTX

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewswire Inc.·
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Entera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biopharmaceutical company developing oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company is advancing its lead candidate EB613 (oral PTH(1-34)) for osteoporosis treatment, which met primary and secondary endpoints in a Phase 2 study, with positive FDA feedback received on planned Phase 3 registrational studies.

Read Full Article at GlobeNewswire Inc.
← Back to Financial Intelligence